Caricamento...
Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSO(TM)), an FDA‐approved third‐generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR‐mutant nonsmall cell lung cancer (NSCLC), limits the long‐term benefits for patients. Thus, effective t...
Salvato in:
| Pubblicato in: | Mol Oncol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7138398/ https://ncbi.nlm.nih.gov/pubmed/32003107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12645 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|